RU2012128509A - Способы лечения заболеваний желудочно-кишечного тракта - Google Patents

Способы лечения заболеваний желудочно-кишечного тракта Download PDF

Info

Publication number
RU2012128509A
RU2012128509A RU2012128509/04A RU2012128509A RU2012128509A RU 2012128509 A RU2012128509 A RU 2012128509A RU 2012128509/04 A RU2012128509/04 A RU 2012128509/04A RU 2012128509 A RU2012128509 A RU 2012128509A RU 2012128509 A RU2012128509 A RU 2012128509A
Authority
RU
Russia
Prior art keywords
cys
asp
glu
tyr
seq
Prior art date
Application number
RU2012128509/04A
Other languages
English (en)
Russian (ru)
Inventor
Марк Дж. Карри
Дэниел П. Зиммер
Ангелика Фретцен
Марко Кесслер
Брайан М. КАЛИ
Original Assignee
Айронвуд Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айронвуд Фармасьютикалз, Инк. filed Critical Айронвуд Фармасьютикалз, Инк.
Publication of RU2012128509A publication Critical patent/RU2012128509A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2012128509/04A 2009-12-07 2010-12-07 Способы лечения заболеваний желудочно-кишечного тракта RU2012128509A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26731609P 2009-12-07 2009-12-07
US61/267,316 2009-12-07
PCT/US2010/059294 WO2011071927A2 (en) 2009-12-07 2010-12-07 Treatments for gastrointestinal disorders

Publications (1)

Publication Number Publication Date
RU2012128509A true RU2012128509A (ru) 2014-01-20

Family

ID=43530704

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012128509/04A RU2012128509A (ru) 2009-12-07 2010-12-07 Способы лечения заболеваний желудочно-кишечного тракта

Country Status (7)

Country Link
US (3) US8735360B2 (enExample)
EP (1) EP2509992B1 (enExample)
JP (2) JP5984675B2 (enExample)
KR (1) KR20120103689A (enExample)
CN (1) CN102822194B (enExample)
RU (1) RU2012128509A (enExample)
WO (1) WO2011071927A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2509992B1 (en) 2009-12-07 2015-10-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
US9527887B2 (en) * 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) * 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
HUE032237T2 (en) * 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
JP2016514671A (ja) * 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
CN113855703B (zh) 2014-12-10 2025-11-25 特里赛达公司 用于口服施用的质子结合聚合物
KR101714448B1 (ko) * 2015-07-10 2017-03-09 가톨릭대학교 산학협력단 위 점막 손상의 예방 및 치료용 조성물 및 헬리코박터 파이로리 균의 우레아제 활성 저해능을 지닌 조성물
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
AU2018360867B2 (en) 2017-11-03 2024-12-12 Tricida, Inc. Compositions for and method of treating acid-base disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216004T3 (es) 1993-10-26 2004-10-16 Thomas Jefferson University Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas.
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU2530199A (en) * 1998-02-06 1999-08-23 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
AU2001256315A1 (en) 2000-04-22 2001-11-07 Ipf Pharmaceuticals Gmbh Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2
GB0105224D0 (en) * 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (de) * 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2006138571A2 (en) * 2005-06-16 2006-12-28 Mohammed Saeed Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
WO2007022531A2 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2650303A1 (en) * 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
PH12012500916B1 (en) * 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
EP2509992B1 (en) 2009-12-07 2015-10-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2011156453A2 (en) 2010-06-09 2011-12-15 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
WO2011071927A3 (en) 2011-10-13
US20140256634A1 (en) 2014-09-11
CN102822194A (zh) 2012-12-12
EP2509992A2 (en) 2012-10-17
US20150119328A1 (en) 2015-04-30
US20130130995A1 (en) 2013-05-23
KR20120103689A (ko) 2012-09-19
JP2013512960A (ja) 2013-04-18
JP5984675B2 (ja) 2016-09-06
US8735360B2 (en) 2014-05-27
EP2509992B1 (en) 2015-10-14
CN102822194B (zh) 2016-10-26
WO2011071927A2 (en) 2011-06-16
JP2016117764A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
JP2013512960A5 (enExample)
JP2013510182A5 (enExample)
FI92326C (fi) LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
RU2011138011A (ru) Миметики аполипопротеина а-i
US20140038881A1 (en) Therapeutic Peptides
CA2779482A1 (en) Treatments for gastrointestinal disorders
US8735360B2 (en) Treatments for gastrointestinal disorders
WO2001007475A1 (en) Novel peptides
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
RU2012105355A (ru) Производное аналога glp-1 или его фармацевтически приемлемые соли и их применение
JP2009108078A5 (enExample)
RU2012109415A (ru) Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
JP2020037570A (ja) オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
HK1213785A1 (zh) 血管紧张素的口服制剂
CA2912635A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
CA2835624A1 (en) Treatments for gastrointestinal disorders
CA2984437A1 (en) Compositions for colon cleansing and the treatment of gastrointestinal disorders
JP5982473B2 (ja) 血清リンを調節するための治療剤
WO2022052471A1 (zh) 双特异性融合多肽化合物
WO2012170766A1 (en) Treatments for gastrointestinal disorders
JP2005060315A (ja) 製剤組成物
EP3452072A2 (en) Novel peptides and peptidomimetics
JP2005126360A (ja) 新規なポリペプチドで構成されたコラゲナーゼ阻害剤
TH145794A (th) สารบำบัดสำหรับความผิดปกติของโรคกระเพาะอาหารและลำไส้ (Gastrointestinal Disorders)
RU2008129731A (ru) Новые пептиды-т-хелперные антигенные детерминанты (thd)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150310